Nothing Special   »   [go: up one dir, main page]

MX2013000908A - Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos. - Google Patents

Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.

Info

Publication number
MX2013000908A
MX2013000908A MX2013000908A MX2013000908A MX2013000908A MX 2013000908 A MX2013000908 A MX 2013000908A MX 2013000908 A MX2013000908 A MX 2013000908A MX 2013000908 A MX2013000908 A MX 2013000908A MX 2013000908 A MX2013000908 A MX 2013000908A
Authority
MX
Mexico
Prior art keywords
sulfatase
acetylgalactosamine
manufacture
highly phosphorylated
phosphorylated human
Prior art date
Application number
MX2013000908A
Other languages
English (en)
Other versions
MX341838B (es
Inventor
Kidisti Araya
Augustus O Okhamafe
Vish Koppaka
Michel Claude Vellard
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2013000908A publication Critical patent/MX2013000908A/es
Publication of MX341838B publication Critical patent/MX341838B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona composiciones de Nacetilgalactosamina-6-s ulfatasa humana, altamente fosforilada (GALNS), y composiciones y formulaciones farmacéuticas de la misma, métodos para producir y purificar GALNS, y su uso en el diagnóstico, profilaxis, o tratamiento de enfermedades y condiciones, incluyendo particularmente enfermedades de almacenamiento lisosomal que son causadas por, o están - asociadas con, una deficiencia en la enzima GALNS, por ejemplo, Mucopolisacaridosis IVa (MPS IVa o síndrome de Morquio A).
MX2013000908A 2010-07-22 2011-07-22 Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos. MX341838B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22
PCT/US2011/045011 WO2012012718A2 (en) 2010-07-22 2011-07-22 Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof

Publications (2)

Publication Number Publication Date
MX2013000908A true MX2013000908A (es) 2013-07-05
MX341838B MX341838B (es) 2016-09-05

Family

ID=44543776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000908A MX341838B (es) 2010-07-22 2011-07-22 Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.

Country Status (28)

Country Link
US (3) US8765437B2 (es)
EP (1) EP2595650B1 (es)
JP (2) JP6030553B2 (es)
KR (2) KR101949906B1 (es)
CN (1) CN103037895B (es)
AR (2) AR082319A1 (es)
AU (1) AU2011280937B2 (es)
BR (1) BR112013001558B1 (es)
CA (2) CA2805673C (es)
CL (2) CL2013000219A1 (es)
CY (1) CY1118934T1 (es)
DK (1) DK2595650T3 (es)
ES (1) ES2616263T3 (es)
HR (1) HRP20170245T1 (es)
HU (1) HUE033163T2 (es)
IL (2) IL224125B (es)
LT (1) LT2595650T (es)
MX (1) MX341838B (es)
PE (3) PE20131140A1 (es)
PL (1) PL2595650T3 (es)
PT (1) PT2595650T (es)
RS (1) RS55669B1 (es)
RU (1) RU2607376C2 (es)
SG (1) SG187580A1 (es)
SI (1) SI2595650T1 (es)
SM (1) SMT201700106B (es)
WO (1) WO2012012718A2 (es)
ZA (1) ZA201300286B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3219795T1 (sl) * 2008-01-18 2024-10-30 Biomarin Pharmaceutical Inc. Izdelava akitvnih visoko fosforiliranih humanih encimov lizomske sulfataze in njihova uporaba
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US20130202633A1 (en) * 2012-02-07 2013-08-08 Saint Louis University, A Non-Profit Organization Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
HUE042373T2 (hu) * 2013-03-13 2019-06-28 Seattle Genetics Inc Aktív szenes szûrés benzodiazepin ADC-k tisztítására
CA2902629A1 (en) * 2013-03-13 2014-10-02 Shire Human Genetic Therapies, Inc. Method of characterizing lysosomal enzymes
RU2692251C2 (ru) * 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
KR101894762B1 (ko) 2013-07-12 2018-09-05 이엠디 밀리포어 코포레이션 표적 단백질을 함유하는 샘플로부터 활성탄을 사용하여 바이러스 제거를 결정하는 방법
WO2016007909A2 (en) * 2014-07-11 2016-01-14 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
WO2021216460A1 (en) * 2020-04-19 2021-10-28 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (ja) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd 純コンドロイチナ−ゼの製造法
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (ru) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Способ получения пектолитического ферментного препарата
DE60233049D1 (de) 2001-01-26 2009-09-03 Selexis Sa Matrix-anheftungsregionen und verfahren zu deren verwendung
WO2004003175A2 (en) * 2002-07-01 2004-01-08 Arkion Life Sciences Llc Process and materials for production of glucosamine and n-acetylglucosamine
PT1592786E (pt) 2003-02-11 2012-01-19 Shire Human Genetic Therapies Diagnóstico e tratamento da deficiência de múltiplas sulfatases e outras utilizando uma enzima geradora de formilglicina (fge)
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
GB2438760A (en) * 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
EP3189831A1 (en) * 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
SI3219795T1 (sl) * 2008-01-18 2024-10-30 Biomarin Pharmaceutical Inc. Izdelava akitvnih visoko fosforiliranih humanih encimov lizomske sulfataze in njihova uporaba
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
KR101598897B1 (ko) 2016-03-03
ES2616263T3 (es) 2017-06-12
EP2595650B1 (en) 2016-11-16
DK2595650T3 (en) 2017-02-27
US20140341878A1 (en) 2014-11-20
IL224125B (en) 2019-02-28
KR20150038715A (ko) 2015-04-08
AR082319A1 (es) 2012-11-28
CL2013000219A1 (es) 2014-07-11
RU2013107765A (ru) 2014-08-27
HUE033163T2 (en) 2017-11-28
EP2595650A2 (en) 2013-05-29
IL260282B (en) 2020-05-31
US8765437B2 (en) 2014-07-01
CN103037895A (zh) 2013-04-10
PE20171798A1 (es) 2017-12-28
AU2011280937B2 (en) 2016-06-09
US20120189605A1 (en) 2012-07-26
KR20130105605A (ko) 2013-09-25
SG187580A1 (en) 2013-03-28
BR112013001558A2 (pt) 2020-08-04
CN103037895B (zh) 2016-11-09
US8940513B2 (en) 2015-01-27
PL2595650T3 (pl) 2017-06-30
BR112013001558B1 (pt) 2022-08-16
PT2595650T (pt) 2017-02-22
PE20171799A1 (es) 2017-12-28
SI2595650T1 (sl) 2017-04-26
AU2011280937A1 (en) 2013-01-31
US20160186149A1 (en) 2016-06-30
RS55669B1 (sr) 2017-06-30
AR119552A2 (es) 2021-12-29
CA2805673A1 (en) 2012-01-26
IL260282A (en) 2018-07-31
LT2595650T (lt) 2017-03-10
US9567572B2 (en) 2017-02-14
CY1118934T1 (el) 2018-01-10
JP6030553B2 (ja) 2016-11-24
KR101949906B1 (ko) 2019-04-22
JP2016178950A (ja) 2016-10-13
CL2017000498A1 (es) 2017-11-24
WO2012012718A3 (en) 2012-04-05
RU2607376C2 (ru) 2017-01-10
CA3146151A1 (en) 2012-01-26
JP2013532986A (ja) 2013-08-22
SMT201700106B (it) 2017-03-08
PE20131140A1 (es) 2013-10-17
HRP20170245T1 (hr) 2017-04-21
ZA201300286B (en) 2014-03-26
MX341838B (es) 2016-09-05
WO2012012718A2 (en) 2012-01-26
CA2805673C (en) 2022-04-05

Similar Documents

Publication Publication Date Title
MX2013000908A (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.
MX2010007846A (es) Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
GB2480987B (en) Enzyme delivery systems and methods of preparations and use
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
MX2011007930A (es) Conjugados de insulina cristalina.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2016001317A (es) Variantes de enzimas.
IN2012DN00943A (es)
IN2012DN02471A (es)
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
WO2012047951A3 (en) Human lung stem cells and uses thereof
MX2019009229A (es) Novedosas variantes enzimaticas que degradan la nicotina.
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
IL194353A0 (en) Lysobactin amides
AR118157A2 (es) Una enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante, composición y sus usos
WO2007031329A3 (de) Verwendung eines kollagens xenogenen ursprungs
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
FG Grant or registration